Tripamide
目录号 : GC70258Tripamide是一种口服活性磺胺类利尿降压药。
Cas No.:73803-48-2
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Tripamide (less than 10 μg/ml) does not modify the membrane potential and resistance, but does suppress the spike evoked by outward current pulses in the presence of 3-5 mM TEA[1].
In the mesenteric artery, Tripamide suppresses the amplitude of e.j.ps evoked by perivascular nerve stimulation. However, the facilitation process produced by repetitive stimulation is less affected by Tripamide[1].
In rats loaded orally with 25 ml/kg of normal saline, Tripamide (0.6-160 mg/kg) increases urine volume and sodium and chloride excretion in a dose-dependent fashion. Only at a dose of 160 mg/kg, there an increase in potassiumexcretion in rats[2].
Tripamide has anti-hypertensive effects, during administration to spontaneously hypertensive rats at a dose of 10 mg/kg/day for 4 weeks, tripamide doubled urine volume and sodium excretion, while potassium excretion is increased by <50% in rats[2].
References:
[1]. H Asada, et al. Effects of N-(4-azo-endo-tricyclo[5.2.1.0.(2.6)]-decan-4-yl)-4-chloro-3-sulfamoylbenzamide (E614; tripamide) on vascular smooth muscles. Gen Pharmaco. 1982;13(3):215-23.
[2]. Philip Hampel, et al. Azosemide is more potent than bumetanide and various other loop diuretics to inhibit the sodium-potassium-chloride-cotransporter human variants hNKCC1A and hNKCC1B. Sci Rep. 2018 Jun 29;8(1):9877.
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.7037 mL | 13.5183 mL | 27.0365 mL |
5 mM | 0.5407 mL | 2.7037 mL | 5.4073 mL |
10 mM | 0.2704 mL | 1.3518 mL | 2.7037 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。